GSK

Business Context and Reporting Period

Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Quarter ended 30 September 2018 (Q3) and Nine Months ended 30 September 2018 (YTD)
Issuance Date: 31 October 2018

GSK reported Q3 sales of £8.1 billion, driven by growth in all three business segments on a Constant Exchange Rate (CER) basis. The company continues to execute its strategy of transitioning from established products to new respiratory and HIV therapies, alongside strong vaccine performance.

Key Financial Metrics

Segment Performance (Q3 2018)

• Pharmaceuticals: £4.2 billion (+1% AER, +3% CER). Growth driven by HIV and new Respiratory products (Nucala, Ellipta portfolio), offset by declines in Seretide/Advair.
• Vaccines: £1.9 billion (+14% AER, +17% CER). Driven by Shingrix and Bexsero.
• Consumer Healthcare: £1.9 billion (-1% AER, +3% CER). Growth in Wellness and Oral health offset by Skin health declines and divestments.

Material Changes vs. Prior Period

• Revenue Growth: Group turnover grew 6% on a CER basis in Q3, with all three businesses delivering CER growth. YTD turnover was flat on an Actual Exchange Rate (AER) basis but grew 4% CER.
• Profitability: Adjusted EPS grew 14% CER in Q3. Total EPS grew 23% CER. Adjusted operating margin improved slightly on a CER basis (+0.2 percentage points) despite price pressures in Respiratory.
• Debt Increase: Net debt increased significantly to £23.8 billion (from £13.2 billion at year-end 2017) primarily due to the £9.3 billion acquisition of Novartis's stake in the Consumer Healthcare Joint Venture in June 2018.
• Restructuring: A new major restructuring programme was approved in July 2018, expected to cost £1.7 billion by 2021 and deliver £400 million in annual savings.

Guidance, Outlook, and Risks

Guidance Update

• 2018 Adjusted EPS: GSK now expects full-year 2018 Adjusted EPS growth of 8-10% CER, tightening the range towards the upper end of previous expectations.
• Shingrix Sales: Full-year 2018 sales guidance for Shingrix has been raised to £700-750 million.
• Tax Rate: The effective tax rate for 2018 is expected to be approximately 19-20% of Adjusted profits.

Management Commentary

CEO Emma Walmsley highlighted strong commercial execution for key products and new launches, particularly Shingrix, alongside effective cost control. The company remains confident in delivering its 2016-2020 outlooks for sales and EPS growth.

Risks and Contingencies

• Currency: A strong Sterling negatively impacted reported growth. If exchange rates hold at Q3 closing rates, the estimated negative impact on full-year 2018 Sterling turnover growth is around 3%.
• Contingent Consideration: Significant accounting charges (£248 million in Q3) arose from re-measuring contingent consideration liabilities related to ViiV Healthcare and Novartis Vaccines acquisitions, driven by exchange rate assumptions and sales forecasts.
• Patent Expiry: Continued decline in Seretide/Advair sales due to generic competition and pricing pressures.

Investor Verification Checklist

• Shingrix Trajectory: Verify if the raised sales guidance (£700-750m) is sustainable given supply allocation processes in the US.
• Advair Impact: Monitor the pace of decline in Advair/Seretide sales and the extent of market share erosion to generics in the US and Europe.
• Debt Servicing: Assess the impact of the increased net debt (£23.8bn) on future interest expenses and credit ratings following the Consumer Healthcare buyout.
• Contingent Liabilities: Review the sensitivity of the £6.2 billion contingent consideration liability to future exchange rate fluctuations and ViiV Healthcare sales performance.
• Restructuring Savings: Track the realization of the £400 million annual savings target from the new 2018 restructuring programme.